Metagenics® Renagen™ DTX: What the Research Shows About Liver, Kidney & Antioxidant Support

Dai Tran, PharmD, MBA, B.S.

CEO & Lead Pharmacist, Khang Pharmacy • CA/MN/TX Licensed Pharmacist

Clinical Insights Series • APhA Immunization Certified • 10+ Years Clinical Experience

The Clinical Question

Metagenics® Renagen™ DTX is a multi-ingredient dietary supplement combining N-acetylcysteine (NAC), Cordyceps mycelium extract (Paecilomyces hepiali), Chinese Salvia root (Salvia miltiorrhiza), and B-vitamins (B6, folate, B12). It is marketed for kidney and liver “detoxification support.”

This article reviews what the published evidence actually supports for each key ingredient, places that evidence in its proper clinical context, and is explicit about what has not been established for the finished Renagen™ DTX product.

Supplement Facts (Per 1-Capsule Serving)

Verify other ingredients, allergens, and serving directions on the current product label before use. Metagenics recommends use under the supervision of a healthcare practitioner.

What the Evidence Does — and Does Not — Establish

• Established (pharmaceutical/clinical use): NAC is a well-established pharmaceutical agent for acetaminophen poisoning antidote therapy at defined doses under clinical supervision. This does not transfer to supplement-dose benefit for healthy adults.
• Large RCT, negative: NAC for contrast-associated acute kidney injury prevention was not supported in the PRESERVE trial (NEJM 2018, PMID: 29130810). Earlier smaller RCTs suggesting benefit were not confirmed by this high-quality evidence.
• Cordyceps (Paecilomyces hepiali): A Cochrane systematic review of Cordyceps sinensis preparations in CKD found largely small trials with methodological limitations. The review does not establish clinical equivalence to the Paecilomyces hepiali extract at 200 mg used in this product.
• Salvia miltiorrhiza (Dan Shen): A 2022 systematic review and meta-analysis of 32 studies (2,264 participants) reported favorable pooled effects on renal-function measures in CKD, but rated certainty of evidence and risk of bias as suboptimal. Findings do not establish efficacy of the 200-mg ingredient in Renagen™ DTX.
• B6 / Folate / B12: These B-vitamins participate in homocysteine metabolism. Homocysteine lowering with B-vitamins has not been shown to reliably improve clinical outcomes in CKD in RCTs.
• Not established: That Renagen™ DTX as a finished product improves GFR, reduces uremic toxins, treats or prevents kidney or liver disease, or enhances organ-level detoxification in healthy adults without documented organ dysfunction.

Ingredient-by-Ingredient Evidence Review

1. N-Acetylcysteine (NAC) — 200 mg

NAC is a precursor to glutathione and has well-documented pharmaceutical applications at defined clinical doses.

Context A — Acetaminophen poisoning antidote [Established pharmaceutical use]

• NAC is an established antidote for acetaminophen poisoning when administered using defined oral or intravenous protocols under clinical supervision. This pharmaceutical use should not be extrapolated to routine supplement-dose NAC in healthy adults.

Context B — Contrast-associated acute kidney injury (CA-AKI) prevention [Large RCT: negative]

• The PRESERVE trial (Weisbord SD et al., NEJM 2018, PMID: 29130810) was a large, well-powered, double-blind RCT in 5,177 high-risk patients undergoing angiography. Oral acetylcysteine was no better than placebo for the primary composite outcome or for contrast-associated AKI. This high-quality evidence did not confirm benefit suggested by earlier smaller trials. NAC for CA-AKI prevention is not an established benefit.

Context C — Oxidative stress markers in CKD/dialysis populations [Limited, surrogate endpoints only]

• Small trials have reported changes in oxidative stress surrogate markers with NAC in hemodialysis populations. These are surrogate endpoints in a specific clinical population and do not establish that 200 mg supplement-dose NAC improves kidney function in healthy adults. Patients with CKD should consult their nephrologist before use.

2. Cordyceps Mycelium Extract (Paecilomyces hepiali) — 200 mg

Cordyceps species have been studied in the context of kidney function, primarily in CKD populations. The specific species in this product, Paecilomyces hepiali, is used as a cordyceps substitute in traditional Chinese medicine and should be distinguished from Cordyceps sinensis (wild-harvested) and Cordyceps militaris (the cultivated species most commonly studied in Western supplement research). The available systematic review evidence covers Cordyceps sinensis preparations and does not directly establish efficacy for this product’s extract.

• A Cochrane systematic review (Zhang HW et al., PMID: 25519252) of Cordyceps sinensis preparations in CKD found that the evidence base consisted largely of small Chinese trials with methodological limitations, including unclear allocation concealment and short study duration. The reviewers were unable to draw firm conclusions about clinical benefit.
• The formula standardizes to 8 mg cordycepic acid and 0.5 mg adenosine per capsule. Whether these marker-compound levels are pharmacologically meaningful in the human kidney context has not been established.
• Evidence level: Cochrane systematic review (indirect — C. sinensis, not P. hepiali); small trials with methodological limitations. Preclinical data support antioxidant and anti-inflammatory mechanisms.
• What this does not establish: That the Paecilomyces hepiali extract in Renagen™ DTX at 200 mg improves kidney function or GFR, or provides kidney detoxification benefits in healthy adults.

3. Chinese Salvia Root (Salvia miltiorrhiza, Dan Shen) — 200 mg

Salvia miltiorrhiza (Dan Shen) contains tanshinones and salvianolic acids, which have antioxidant and anti-inflammatory properties in laboratory settings. It has been studied in cardiovascular and renal contexts in human trials.

• A 2022 systematic review and meta-analysis (Zhang W et al., PMID: 35747383) of 32 studies involving 2,264 participants reported favorable pooled effects of Salvia miltiorrhiza preparations on several renal-function measures in CKD populations, including serum creatinine, 24-hour urinary protein, creatinine clearance, and GFR. However, the authors rated the certainty of evidence and risk-of-bias profile as suboptimal. Preparations and doses varied substantially across included studies.
• These findings do not establish efficacy of the 200-mg Salvia miltiorrhiza ingredient in Renagen™ DTX, as the preparations studied differed from this product’s formulation and dose.
• In vitro and animal studies document antifibrotic, antioxidant, and anti-inflammatory effects of tanshinone and salvianolic acid constituents. These are preclinical findings.
• Evidence level: Systematic review with favorable pooled signals but suboptimal certainty and risk-of-bias ratings; preclinical mechanistic data.
• What this does not establish: That Salvia miltiorrhiza at 200 mg in this supplement improves kidney or liver function in healthy adults or provides kidney detoxification benefits.

4. B-Vitamins: B6 (10 mg), Folate (680 mcg DFE), B12 (125 mcg)

This formula provides vitamin B6 as pyridoxine HCl, folate as calcium L-methylfolate, and vitamin B12 as methylcobalamin. These B-vitamins participate in one-carbon metabolism and homocysteine metabolism.

• Hyperhomocysteinemia is common in CKD and has been associated with cardiovascular risk and CKD progression in epidemiological studies. B-vitamin supplementation lowers homocysteine levels reliably.
• However, multiple large RCTs have found that homocysteine lowering with B-vitamins does not reliably reduce cardiovascular events or slow CKD progression, despite correcting the biochemical marker. The HOST trial and others demonstrated this dissociation between homocysteine lowering and clinical outcomes in CKD patients.
• Evidence level: Established biochemical function (homocysteine lowering). Clinical outcome benefit in CKD or liver disease: not established by RCT evidence for B-vitamin supplementation alone.
• What this does not establish: That these B-vitamins in this formula prevent kidney disease, enhance detoxification, or produce clinical organ-protection benefits beyond their established biochemical roles.

Important Safety Considerations

Who May Consider Renagen™ DTX?

• Healthy adults in clinician-supervised integrative protocols where a practitioner has reviewed their history, medication list, and identified a specific rationale for this formula
• Not appropriate for self-directed use by: Individuals taking anticoagulants, antihypertensives, diabetes medications, digoxin, or nitroglycerin; those with CKD, liver disease, or elevated liver enzymes requiring clinical evaluation; or anyone seeking to self-manage kidney or liver function concerns. These situations require physician or specialist evaluation — not supplement self-direction.

Pharmacist’s Note

As a PharmD, I am careful to distinguish between the individual ingredient evidence for the components of Renagen™ DTX and what has been established for the finished product. The NAC component has a strong pharmaceutical evidence base for acetaminophen poisoning under clinical protocols; the PRESERVE trial (PMID: 29130810) showed NAC did not prevent contrast-associated AKI in a large, well-powered RCT. The Paecilomyces hepiali Cordyceps extract has indirect support from a Cochrane review of Cordyceps sinensis in CKD — but species and formulation differ and that evidence cannot be assumed to transfer directly. Salvia miltiorrhiza has the most encouraging human evidence in this formula via a 2022 meta-analysis of 32 studies, though certainty ratings were suboptimal. The B-vitamin components support homocysteine metabolism but have not been shown to improve kidney or liver clinical outcomes in RCTs beyond correcting the biochemical marker.

I do not present Renagen™ DTX as a kidney or liver detoxification product. Given the manufacturer’s explicit contraindications with blood thinners, antihypertensives, diabetes medications, digoxin, and nitroglycerin, I conduct a thorough medication review before any discussion of this supplement. For patients with CKD or liver disease, I refer to their nephrologist or hepatologist. Free PharmD consultation: (408) 622-8068.

This product carries manufacturer contraindications with multiple drug classes. Do not use without pharmacist or physician review of your full medication list.

Frequently Asked Questions

Q: Does Renagen™ DTX detoxify my kidneys?
A: The kidneys filter blood and excrete water-soluble waste products as part of normal physiology. There is no established clinical evidence that Renagen™ DTX as a finished product enhances this process in healthy adults. If you have concerns about kidney function, this requires medical evaluation — not self-directed supplementation.

Q: I heard NAC protects the kidneys during CT scans. Is that true?
A: This was a widely held belief based on older smaller trials, but the PRESERVE trial — a large well-powered RCT in over 5,000 high-risk patients — found that oral NAC was no better than placebo for preventing contrast-associated acute kidney injury.

Q: Can I take this if I have kidney disease?
A: No supplement, including Renagen™ DTX, should be self-directed in the setting of kidney disease. Please consult your nephrologist.

Q: I take warfarin. Is this safe?
A: No — the manufacturer explicitly contraindicates use with blood-thinning medications, and Salvia miltiorrhiza has a documented interaction with warfarin. Do not use this product if you are taking warfarin or any anticoagulant without physician and pharmacist review.

Related Clinical Insights Articles

• Ultra Binder®: What the Research Shows About GI Binding Ingredients & Detox Claims →

Selected Key References

1. MIXED / NEGATIVE RCT Weisbord SD, Gallagher M, Jneid H, et al. Outcomes after Angiography with Sodium Bicarbonate and Acetylcysteine. N Engl J Med. 2018;378(7):603–614. PMID: 29130810. DOI: 10.1056/NEJMoa1710933.
   PRESERVE trial: double-blind RCT in 5,177 high-risk patients undergoing angiography. Oral acetylcysteine was no better than placebo for the primary composite outcome or for contrast-associated AKI. This high-quality evidence did not confirm benefit suggested by earlier smaller trials.
2. SYSTEMATIC REVIEW Zhang HW, Lin ZX, Tung YS, et al. Cordyceps sinensis (a traditional Chinese medicine) for treating chronic kidney disease. Cochrane Database Syst Rev. 2014;(12):CD008353. PMID: 25519252. DOI: 10.1002/14651858.CD008353.pub2.
   Cochrane systematic review of Cordyceps sinensis preparations in CKD populations. Evidence consisted largely of small Chinese trials with methodological limitations including unclear allocation concealment and short duration; reviewers were unable to draw firm conclusions about clinical benefit. Importantly, this review evaluated Cordyceps sinensis preparations and does not establish clinical equivalence to the Paecilomyces hepiali extract or 200-mg dose used in Renagen™ DTX.
3. SYSTEMATIC REVIEW / META-ANALYSIS Zhang W, Li J, Yang P, et al. Efficacy and Safety of Salvia miltiorrhiza for Treating Chronic Kidney Diseases: A Systematic Review and Meta-Analysis. Evid Based Complement Alternat Med. 2022;2022:2117433. PMID: 35747383. DOI: 10.1155/2022/2117433.
   Systematic review and meta-analysis of 32 studies involving 2,264 participants. Pooled results favored Salvia miltiorrhiza preparations for several renal measures including serum creatinine, 24-hour urinary protein, creatinine clearance, and GFR in CKD populations. Authors rated certainty of evidence and risk-of-bias profile as suboptimal. Preparations and doses varied substantially across included studies. Findings do not establish efficacy of the 200-mg Salvia miltiorrhiza ingredient in Renagen™ DTX.

Reviewed by: Dai Tran, PharmD, MBA, B.S.  View full bio →

CEO & Lead Pharmacist, Khang Pharmacy • CA/MN/TX Licensed Pharmacist

Clinical Insights Series • APhA Immunization Certified • 10+ Years Clinical Experience

Khang Pharmacy | 2451 S King Rd., Ste A1, San Jose, CA 95122 | (408) 622-8068 | www.khangpharmacy.com